Repurposing Radiation Therapy for Immuno-oncology

被引:9
作者
Tang, J. [1 ]
Malachowska, B. [2 ]
Wu, X. [3 ]
Guha, C. [1 ]
机构
[1] Montefiore Med Ctr, Dept Radiat Oncol, 111 E 210th St, Bronx, NY 10467 USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Fudan Univ Canc Hosp, Shanghai Engn Res Ctr Proton & Heavy Ion Radiat T, Dept Med Phys, Shanghai Proton & Heavy Ion Ctr, Shanghai, Peoples R China
关键词
Immunobiological models; immunomodulation; radiation therapy; relative immunological effectiveness; CARBON-ION-BEAMS; CELL LUNG-CANCER; PANCREATIC-CANCER; TUMOR-CELLS; RADIOTHERAPY; BLOCKADE; IMMUNOTHERAPY; EFFICACY; MULTICENTER; IRRADIATION;
D O I
10.1016/j.clon.2021.08.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Radiation therapy is traditionally used for the local control of tumour growth, but recent studies suggest that radiation therapy can have immunomodulatory properties that can be applied in combination therapy with immunotherapeutic agents. The paradigm of using radiation therapy for immunomodulation in cancer treatment is a rapidly progressing field, with multiple ongoing clinical trials exploring its use in combination with immune checkpoint blockades to induce an abscopal effect. Permutations of radiation therapy regimens, including variations in radiation dosing, radiation planning parameters and radiation modality, are being tested with varying degrees of success. The relative biological effectiveness was a concept introduced in the early days of radiation biology that allows the comparison of local tumour control across various radiation modalities and energies. Similarly, there remains a need for a new concept of comparing the immunological effectiveness of various radiation modalities. In this review, we will provide an overview of immunobiological models for preclinical and clinical monitoring of radiation therapy regimens and introduce the concept of relative immunological effectiveness to compare and screen for immune-activating functions of these regimens. (c) 2021 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.
引用
收藏
页码:683 / 693
页数:11
相关论文
共 72 条
[1]   Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].
Antonia, S. J. ;
Villegas, A. ;
Daniel, D. ;
Vicente, D. ;
Murakami, S. ;
Hui, R. ;
Kurata, T. ;
Chiappori, A. ;
Lee, K. H. ;
de Wit, M. ;
Cho, B. C. ;
Bourhaba, M. ;
Quantin, X. ;
Tokito, T. ;
Mekhail, T. ;
Planchard, D. ;
Kim, Y. -C. ;
Karapetis, C. S. ;
Hiret, S. ;
Ostoros, G. ;
Kubota, K. ;
Gray, J. E. ;
Paz-Ares, L. ;
Carpeno, J. de Castro ;
Faivre-Finn, C. ;
Reck, M. ;
Vansteenkiste, J. ;
Spigel, D. R. ;
Wadsworth, C. ;
Melillo, G. ;
Taboada, M. ;
Dennis, P. A. ;
Ozguroglu, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350
[2]   Radiotherapy and Immunotherapy for Cancer: From "Systemic" to "Multisite" [J].
Arina, Ainhoa ;
Gutiontov, Stanley I. ;
Weichselbaum, Ralph R. .
CLINICAL CANCER RESEARCH, 2020, 26 (12) :2777-2782
[3]   Ionizing radiation modulates the phenotype and function of human CD4+induced regulatory T cells [J].
Beauford, Samantha S. ;
Kumari, Anita ;
Garnett-Benson, Charlie .
BMC IMMUNOLOGY, 2020, 21 (01)
[4]  
Bonnotte B, 2003, CANCER RES, V63, P2145
[5]   Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 "PembroRad" randomized trial [J].
Bourhis, J. ;
Sire, C. ;
Tao, Y. ;
Martin, L. ;
Alfonsi, M. ;
Prevost, J. B. ;
Rives, M. ;
Lafond, C. ;
Tourani, J. M. ;
Biau, J. ;
Geoffrois, L. ;
Coutte, A. ;
Liem, X. ;
Vauleon, E. ;
Drouet, F. ;
Pechery, A. ;
Guigay, J. ;
Wanneveich, M. ;
Auperin, A. ;
Sun, X. .
ANNALS OF ONCOLOGY, 2020, 31 :S1168-S1168
[6]   Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences [J].
Brix, Nikko ;
Tiefenthaller, Anna ;
Anders, Heike ;
Belka, Claus ;
Lauber, Kirsten .
IMMUNOLOGICAL REVIEWS, 2017, 280 (01) :249-279
[7]   External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing [J].
Chakraborty, M ;
Abrams, SI ;
Coleman, CN ;
Camphausen, K ;
Schlom, J ;
Hodge, JW .
CANCER RESEARCH, 2004, 64 (12) :4328-4337
[8]   Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy [J].
Chakraborty, M ;
Abrams, SI ;
Camphausen, K ;
Liu, KB ;
Scott, T ;
Coleman, CN ;
Hodge, JW .
JOURNAL OF IMMUNOLOGY, 2003, 170 (12) :6338-6347
[9]  
Chen Yingtai, 2014, Zhonghua Zhong Liu Za Zhi, V36, P435
[10]   Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients [J].
Chow, Jacky ;
Hoffend, Nicholas C. ;
Abrams, Scott, I ;
Schwaab, Thomas ;
Singh, Anurag K. ;
Muhitch, Jason B. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (38) :23721-23729